Thrivent Financial for Lutherans Reduces Position in Qiagen (NYSE:QGEN)

Thrivent Financial for Lutherans decreased its stake in shares of Qiagen (NYSE:QGEN) by 4.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,590 shares of the company’s stock after selling 580 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Qiagen were worth $558,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Riverview Trust Co acquired a new position in shares of Qiagen in the 1st quarter valued at $28,000. Park Place Capital Corp purchased a new stake in Qiagen during the 1st quarter valued at about $36,000. Quarry LP acquired a new position in shares of Qiagen in the fourth quarter valued at about $38,000. CWM LLC raised its stake in shares of Qiagen by 19.1% in the first quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after purchasing an additional 358 shares during the last quarter. Finally, Headlands Technologies LLC lifted its holdings in shares of Qiagen by 396.6% during the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after purchasing an additional 2,189 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on QGEN. Robert W. Baird increased their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. increased their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 18th. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a report on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.25.

Qiagen Stock Performance

QGEN opened at $43.55 on Wednesday. The firm has a fifty day moving average price of $45.36 and a 200 day moving average price of $43.48. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.44. The stock has a market cap of $9.94 billion, a P/E ratio of 29.20, a P/E/G ratio of 3.16 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The business had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. During the same quarter in the prior year, the firm posted $0.53 earnings per share. The company’s revenue was down .2% compared to the same quarter last year. Equities research analysts anticipate that Qiagen will post 2.15 earnings per share for the current year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.